Skip to content

High-intensity Interval Training Versus Moderate Continuous Training in Heart Transplant Recipients.

High-intensity Interval Training Versus Moderate Continuous Training in Heart Transplant Recipients With Impaired Chronotropic Response: A Randomized Controlled Crossover Trial.

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01914406
Enrollment
20
Registered
2013-08-02
Start date
2011-01-31
Completion date
2013-10-31
Last updated
2023-10-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Transplant Recipients

Keywords

Heart transplant recipients, Exercise capacity, endothelial function, Quality of life

Brief summary

The aim of this study was to examine the effects of high intensity aerobic interval training (AIT) versus moderate continuous training (CON) in heart transplant recipients.

Detailed description

Clinically stable heart transplant recipients \> 12 month or more after HTx, age \> 18 years, willing and capable of giving written informed consent for study participation and anticipated to be able to participate in the study for 12 months were included from the Heart Centre, Rigshospitalet, Copenhagen University Hospital. Patients were excluded due to unstable condition or postoperative complications, recent severe rejection episodes (\>H1R \< 3 month), physical disabilities which prevent participation and re-transplantation or multi-organtransplantation.

Interventions

Each AIT session consisted a 10 minute warm-up period followed by 16 minutes of interval training consisting of intervals of 4-3-2 and 1 minutes duration at 85-95% of their peak capacity separated by 2-4 min active rest.

OTHERcontinuous moderate training

Continued exercise 45 min.

Sponsors

Bispebjerg Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

-stable Heart transplant recipients \> 12 month or more after HTx, age \> 18 years,\< 80. willing and capable of giving written informed consent for study participation.

Exclusion criteria

unstable condition postoperative complications, recent severe rejection episodes (\>H1R \< 3 month), re-transplantation or multi-organtransplantation.

Design outcomes

Primary

MeasureTime frameDescription
VO2peakbaseline test (inclusion), follow-up 1(3 month), follow-up 2 (8 month), follow-up 3 (11 month).baseline test before randomization 1. follow-up after 12 weeks of exercise 2. follow-up after 5 month washout. 3. follow-up after second 12 weeks period of exercise.

Secondary

MeasureTime frameDescription
Bloodsamples/biomarkers.baseline test (inclusion), follow-up 1(3 month), follow-up 2 (8 month), follow-up 3 (11 month).Samples cooled on ice, centrifuged for 10 minutes and the plasma transferred to microtubes and stored at -80°C. Biomarkers analysed at department of biomedicine at University of Copenhagen.
augmentation index (AI), endoPATbaseline test (inclusion), follow-up 1(3 month), follow-up 2 (8 month), follow-up 3 (11 month).Augmentation index (AI)derived from pulse wave analyses and is a measure of arterial stiffness, (EndoPAT).
Endothelial function (endoPAT)baseline test (inclusion), follow-up 1(3 month), follow-up 2 (8 month), follow-up 3 (11 month).After the release of the cuff the hyperemic response was recorded and the reactive hyperemia index (RHI) was calculated automatic independent of operator. (endoPAT)
Quality of Life (QoL)SF-36baseline test (inclusion), follow-up 1(3 month), follow-up 2 (8 month), follow-up 3 (11 month).SF-36, information on Quality of Life
HADS-a, HADS-d anxiety and depressionbaseline test (inclusion), follow-up 1(3 month), follow-up 2 (8 month), follow-up 3 (11 month).Symptoms of anxiety and depression measured by the Hospital Anxiety and Depression Scale (HADS).

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026